Evidence map›Paper›PMID 33071699›Full record

ArticleDer Pneumologe2020

[Pulmonary involvement in cancers].

Niels Reinmuth, Sarah-Christin Mavi

Open access · bronzeAbstract readEnglish Abstract
In one paragraph

Article in Der Pneumologe, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 79% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Niels ReinmuthAbteilung für Thorakale Onkologie, Asklepios Fachkliniken München-Gauting, Robert-Koch-Allee 2, 82131 Gauting, Deutschland.
Sarah-Christin MaviAbteilung für Pneumologie, Asklepios Fachkliniken München-Gauting, 82131 Gauting, Deutschland.
Asklepios Fachkliniken München-Gauting · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The lungs are often involved in tumors and are affected in a wide variety of ways. Lung cancer comprises one of the most common cancer entities and has been characterized by a vast expansion of treatment approaches in recent years. Moreover, the lungs are a common metastatic site of multiple other cancer entities. Various treatment modalities, such as tyrosine kinase inhibitors, checkpoint inhibitors, chimeric antigen receptor cell therapy, and radiotherapy approaches can cause pulmonary side effects. Finally, many patients suffer from pulmonary comorbidities which may mutually impact the clinical course and prognosis of the cancer disease. As examples, various aspects, such as pulmonary veno-occlusive disease, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis are discussed.

Indexed as

Idiopathic pulmonary fibrosisLung cancerNeoplasm metastasisPulmonary disease, chronic obstructivePulmonary veno-occlusive disease

Identifiers

PMID33071699
PMCPMC7550836
OpenAlexW3093419094

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.